Trial Profile
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase II Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Feb 2024
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 03 Jul 2023 Planned End Date changed from 1 Sep 2023 to 1 Sep 2024.
- 03 Jul 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Sep 2024.
- 14 Dec 2021 Plasma cells from bone marrow (BM) samples from patients from this and another study (NCT03290950) were used to predict genomic and immune signatures, presented at the 63rd American Society of Hematology Annual Meeting and Exposition.